IVVD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IVVD is not a good buy right now for a beginner, long-term investor with $50,000-$100,000 to deploy. The stock is deeply oversold and near support, but the trend is still bearish, the AI Stock Picker and SwingMax both show no signal, hedge funds are selling aggressively, and the company just had a revenue miss that triggered a sharp selloff. I would not buy it here; the current setup is more of a wait-and-watch than a high-conviction long-term entry.
Current price is 1.16 in pre-market, slightly above the S1 support zone at 1.197 and near S2 at 1.088, which shows the stock is trading at the lower end of its range. RSI_6 at 19.652 indicates it is oversold, but the MACD histogram is negative and expanding, which confirms bearish momentum remains intact. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5, so the broader trend is still down. The short-term picture is oversold but not reversed, meaning the stock can bounce, yet the trend has not turned bullish.
["H.C. Wainwright reiterated a Buy rating with a $10 price target, suggesting substantial upside if the VYD2311 thesis plays out.", "Analyst commentary says the Q1 revenue miss may be more seasonal and timing-related than a deterioration in the core story.", "Strong recruitment progress in the DECLARATION study.", "Reduced post-dose monitoring time for drug 2311 to 30 minutes, which may improve practical adoption.", "Q1 2026 revenue still grew 21.6% year over year."]
["The market reacted sharply to a Q1 revenue miss and higher-than-expected R&D expense.", "Hedge funds are selling, and the selling amount increased 433.14% over the last quarter.", "Insiders are neutral with no meaningful recent buying support.", "MACD remains bearish and moving averages are stacked in a downtrend.", "No AI Stock Picker or SwingMax signal is present.", "Near-term stock pattern analysis suggests limited upside and weak next-month performance."]
Latest quarter appears to be Q1 2026. Revenue was $13.74 million, up 21.6% year over year, but the company posted a loss of -$0.13 per share and missed revenue expectations, which pressured the stock. R&D expense was $30.7 million, reflecting heavy investment ahead of the key VYD2311 readout. Growth exists, but profitability remains weak and spending is elevated.
Recent analyst tone is still constructive despite the selloff. On 2026-05-14, H.C. Wainwright said the drop was likely overdone, reiterated a Buy rating, and maintained a $10 price target. The bullish case centers on VYD2311 and a potential BLA, while the bearish case is the Q1 miss, elevated R&D spend, and weak current share price action. Wall Street pros appear optimistic on the long-term pipeline, but the near-term tape and sentiment remain negative.
